MK-2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

MK-2206 will be taken orally once a week for four weeks (one cycle). Treatment will
continue for as long as a subject is benefitting from the study drug.

During each cycle subjects will have a physical exam, blood samples and an EKG (first 2
cycles). Every 2 cycles a CT scan or MRI of chest, stomach area, and pelvis will be
performed. Optional tumor biopsies may be performed.

Inclusion Criteria:

- Grade 2 or 3 ovarian, fallopian tube, or primary peritoneal cancer

- Evidence of a defect in the P13K/AKT pathway

- Prior platinum-based chemotherapy

- Life expectancy > 6 months

- Normal organ and marrow function

- Toxicities from prior therapy resolved

- Able to tolerate oral medications

Exclusion Criteria:

- Pregnant or breastfeeding

- Receiving other study agents

- Brain metastases

- Subjects requiring insulin for control of hyperglycemia

- Prolonged QTc interval

- Preexisting significant heart block or bradycardia due to cardiac disease

- Uncontrolled intercurrent illness

- Bowel obstruction

- Dependency on IV hydration or TPN

- History of a different malignancy unless disease free for the last 5 years

- HIV-positive on combination antiretroviral therapy